CC-93269 is a T-cell bi-specific antibody targeting both BCMA and CD3 in patients with multiple myeloma.
| SparkCures ID | 311 |
|---|---|
| Developed By | Celgene Corporation |
| Generic Name | CC-93269 |
| Treatment Classifications | |
| Treatment Targets |
There are no resources, links or videos to display for this treatment.